Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Platelet-derived growth factor D: tumorigenicity in mice and dysregulated expression in human cancer.

LaRochelle WJ, Jeffers M, Corvalan JR, Jia XC, Feng X, Vanegas S, Vickroy JD, Yang XD, Chen F, Gazit G, Mayotte J, Macaluso J, Rittman B, Wu F, Dhanabal M, Herrmann J, Lichenstein HS.

Cancer Res. 2002 May 1;62(9):2468-73.

2.

Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy.

Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG.

Crit Rev Oncol Hematol. 2001 Apr;38(1):17-23. Review.

PMID:
11255078
3.

Transgenic mice as a source of fully human antibodies for the treatment of cancer.

Davis CG, Gallo ML, Corvalan JR.

Cancer Metastasis Rev. 1999;18(4):421-5.

PMID:
10855785
4.

Production of protective human antipneumococcal antibodies by transgenic mice with human immunoglobulin loci.

Russell ND, Corvalan JR, Gallo ML, Davis CG, Pirofski La.

Infect Immun. 2000 Apr;68(4):1820-6.

5.

Fully human anti-interleukin-8 monoclonal antibodies: potential therapeutics for the treatment of inflammatory disease states.

Yang XD, Corvalan JR, Wang P, Roy CM, Davis CG.

J Leukoc Biol. 1999 Sep;66(3):401-10.

PMID:
10496309
6.

Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy.

Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG, Jakobovits A.

Cancer Res. 1999 Mar 15;59(6):1236-43.

7.

Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice.

Mendez MJ, Green LL, Corvalan JR, Jia XC, Maynard-Currie CE, Yang XD, Gallo ML, Louie DM, Lee DV, Erickson KL, Luna J, Roy CM, Abderrahim H, Kirschenbaum F, Noguchi M, Smith DH, Fukushima A, Hales JF, Klapholz S, Finer MH, Davis CG, Zsebo KM, Jakobovits A.

Nat Genet. 1997 Feb;15(2):146-56. Erratum in: Nat Genet 1997 Aug;16(4):410.

PMID:
9020839
8.

Therapy of streptozotocin induced diabetes with a bifunctional antibody that delivers vinca alkaloids to IL-2 receptor positive cells.

Kuus-Reichel K, Knott C, Sam-Fong P, Petrella E, Corvalan JR.

Autoimmunity. 1995;22(3):173-81.

PMID:
8734571
9.

Reduction of toxicity of a vinca alkaloid by an anti-vinca alkaloid antibody.

Gutowski MC, Fix DV, Corvalan JR, Johnson DA.

Cancer Invest. 1995;13(4):370-4.

PMID:
7627723
10.

Production and in vivo characterization of a bifunctional antibody (IVA039.1) with specificity for the mouse interleukin-2 receptor and vinca alkaloids.

Kuus-Reichel K, Knott CL, Sam-Fong P, Jue RA, Mackensen DG, Corvalan JR.

Hybridoma. 1994 Apr;13(2):115-22.

PMID:
8050776
11.

In vivo antitumor activity of a panel of four monoclonal antibody-vinca alkaloid immunoconjugates which bind to three distinct epitopes of carcinoembryonic antigen.

Starling JJ, Maciak RS, Hinson NA, Nichols CL, Briggs SL, Laguzza BC, Smith W, Corvalan JR.

Bioconjug Chem. 1992 Jul-Aug;3(4):315-22.

PMID:
1382618
12.

Immunoglobulins secreted by a hybrid-hybridoma: analysis of chain assemblies.

Smith W, Jarrett AL, Beattie RE, Corvalan JR.

Hybridoma. 1992 Feb;11(1):87-98.

PMID:
1737643
13.

Suppression of well-established tumour xenografts by a hybrid-hybrid monoclonal antibody and vinblastine.

Smith W, Gore VA, Brandon DR, Lynch DN, Cranstone SA, Corvalan JR.

Cancer Immunol Immunother. 1990;31(3):157-63.

PMID:
2186853
14.

New antitumor monoclonal antibody-vinca conjugates LY203725 and related compounds: design, preparation, and representative in vivo activity.

Laguzza BC, Nichols CL, Briggs SL, Cullinan GJ, Johnson DA, Starling JJ, Baker AL, Bumol TF, Corvalan JR.

J Med Chem. 1989 Mar;32(3):548-55.

PMID:
2783975
15.

Development of a dual label fluorescence technique that can be utilized to elucidate the mechanism of action of monoclonal antibody-drug conjugates.

Starling JJ, Hinson NA, Marder P, Maciak RS, Laguzza BC, Corvalan JR, Smith W.

Cancer Res. 1988 Nov 1;48(21):6211-6.

16.
17.

Increased therapeutic effect of vinca alkaloids targeted to tumour by a hybrid-hybrid monoclonal antibody.

Corvalan JR, Smith W, Gore VA, Brandon DR, Ryde PJ.

Cancer Immunol Immunother. 1987;24(2):138-43.

PMID:
3829048
20.

Antitumor properties of vindesine-monoclonal antibody conjugates.

Rowland GF, Axton CA, Baldwin RW, Brown JP, Corvalan JR, Embleton MJ, Gore VA, Hellström I, Hellström KE, Jacobs E, et al.

Cancer Immunol Immunother. 1985;19(1):1-7.

PMID:
3844970
21.
22.

T helper cells required for the in vitro primary antibody response to SRBC are neither SRBC-specific nor MHC-restricted.

Feeney AJ, Corvalan JR, Matzinger P, Howard JC.

J Mol Cell Immunol. 1984;1(4):211-22.

PMID:
6242859
23.

Use of monoclonal antibodies for the histopathological diagnosis of human malignancy.

Gatter KC, Abdulaziz Z, Beverley P, Corvalan JR, Ford C, Lane EB, Mota M, Nash JR, Pulford K, Stein H, Taylor-Papadimitriou J, Woodhouse C, Mason DY.

J Clin Pathol. 1982 Nov;35(11):1253-67.

25.

T-cell hybrids as a source of antigen-specific factors.

Taussig MJ, Holliman A, Corvalán JR.

Transplant Proc. 1980 Sep;12(3):427-31. No abstract available.

PMID:
6164137
26.

Immunological activity of a T hybrid line. I. Production of an H-2-related suppressor factor with specificity for sheep red blood cells.

Taussig MJ, Corvalán JR, Binns RM, Roser B, Holliman A.

Eur J Immunol. 1979 Oct;9(10):768-76.

PMID:
93051
27.

Demonstration of MHC-specific haemolytic plaque-forming cells.

Howard JC, Corvalan JR.

Nature. 1979 Mar 29;278(5703):449-51. No abstract available.

PMID:
377088
28.

Production of an H--2-related suppressor factor by a hybrid T-cell line.

Taussig MJ, Corvalan JR, Binns RM, Holliman A.

Nature. 1979 Jan 25;277(5694):305-8. No abstract available.

PMID:
84337
29.

Characterization of an antigen-specific factor from a hybrid T-cell line.

Taussig MJ, Corvalán JR, Holliman A.

Ann N Y Acad Sci. 1979;332:316-35. No abstract available.

PMID:
93865

Supplemental Content

Loading ...
Support Center